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Epilepsy is a disorder of the brain characterized by an enduring predisposition 
to generate seizures. Infectious agents are mentioned in its etiology. With 
identifying and appropriate treatment of these infectious agents, preventing their 
secondary outcomes, including seizure is possible. This study was conducted 
to determine frequency of anti-Toxoplasma antibodies (IgG, IgM) and anti-
Toxocara antibody (IgG) in epileptic patients. 
Materials & Methods
Study sample consisted of 141 epileptic patients and 144 healthy people. After 
obtaining informed consents and completing demographic questionnaire, serum 
samples were taken from participants. The diagnostic test of Toxoplasma IgG & 
IgM and Toxocara antibodies was performed under the same conditions using 
ELISA method in a qualified private laboratory. Samples from patients and 
control groups with positive ELISA test in terms of anti-Toxocara antibody were 
also used for confirmatory Western blot test.
Result
According to ELISA results, 28 (19.85%) epileptic patients and 2(1.38%) of 
healthy people had anti-Toxocara antibodies (P<001), while 39 (30.46%) of the 
control group people and 14.18% of patients had anti-Toxoplsma antibodies 
(P=0.001).
Conclusion
Frequency of anti-Toxoplasma gondii is lower in epileptic than healthy individuals 
and this result is contrary to investigations that have reported higher levels of 
this antibody in such patient groups. ELISA results for Toxocara showed that 
the frequency of anti-Toxocara antibody in epileptic patients might empower the 
probability that this parasite may cause central nervous system damage. Western 





“Epilepsy is a disorder of the brain characterized by an enduring predisposition 
to generate seizures and by the neurobiologic, cognitive, psychological and social 
consequences of this condition”(1). Clinical presentations are caused by different 
attacks, and depend on which part of the brain is impaired (2, 3).
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(13), while this parasite is not involved in pathogenesis 
of epilepsy, and merely there is a high prevalence of this 
parasite in epileptic patients (14).
Serological techniques are the main methods in 
identifying Toxoplasma and ELISA is the most 
common serology test to identify Toxocara sp, which 
uses excretory/secretory (E-S) parasitic antigens. It 
seems, under unfavorable conditions, antigens E-S 
allows Toxocara to escape the host immunity and 
survive. Besides, due to potential cross-reaction with 
other intestinal nematodes such as Ascaris, Western 
blot confirmatory test is used, which is also based on 
parasitic antigens E-S reaction with antibodies in suspect 
person’s serum after a certain time (15, 16).
In Iran, a high prevalence of Toxoplasma infection has 
been reported in various groups (7, 17). Toxocariasis is 
a helminth zoonotic infection, which is preventable (18). 
Furthermore, there are contradictory results about the 
role of Toxocara and Toxoplasma in etiology of epilepsy 
(13, 14). 
Therefore, this study was conducted to determine the 
frequency of serum anti-Toxoplasma specific antibodies 
(IgG, IgM) and anti-Toxocara specific antibody (IgG) 
in epileptic patients and comparing them with healthy 
people as control groups. 
Materials & Methods
Sampling
Study sample consisted of 141 patients presenting to 
neurology clinic (Dept. of Pediatrics, Neurology Ward, 
Ahvaz Jundishapur University of Medical Sciences, 
Ahvaz, Iran), with psychiatric records at health center 
and diagnosis of epilepsy whose electroencephalography 
(EEG), brain CT scan or MRI had been reviewed 
by neurologist in the Neurology Department of the 
Jundishapur University of Medical Sciences in 2014, 
and 144 healthy people from general population without 
a history of previous seizures or their families (as the 
control group).
The types of seizure were defined according to the 
International League against Epilepsy (ILAE) 2001 
classification (19). We selected 117 patients with 
idiopathic seizure, 10 patients with febrile seizure 
(Special syndrome) and 14 patients with generalized 
seizure. Patient and control groups were selected 
Burden of the disease is estimated at 0.5%, and of 50 
million people worldwide that suffer from this disease, 
more than 80% have not been cured (4). 
Infectious agents are mentioned in its etiology. 
Identifying these agents and preventing their secondary 
outcomes, including seizure, is an important step 
forward. In examining infectious agents, studies indicate 
the role of some helminths and protozoa such as Taenia 
sollium, Toxoplasma, Toxocara sp., and Plasmodium in 
causing epileptic attacks (5, 6).
Toxoplasma gondii infection is one of the most 
common parasitic infections in humans and other 
warm-blooded animals with worldwide distribution. 
T. gondii is compulsive intracellular protozoa and 
asymptomatic in latent form in healthy people, and in 
immunocompromised patients, cerebral toxoplasmosis 
can cause seizures and intracranial mass lesions (7). 
The latent form of T. gondii is a common and dormant 
infection in the brain and has the potential to cause 
epilepsy (8).
Recently, neuropathophysiological studies indicate a 
relationship between formation of microglial nodule 
in Toxoplasma infection and epilepsy. This finding 
increases the likelihood of infection as a cause of 
epilepsy (9).
Another parasitic infection that increases likelihood of 
epilepsy is Toxocara, a nematode worm of acaridae 
family that exists in small intestines of their natural hosts, 
including cats and dogs. Eggs containing second-stage 
larvae are accidentally ingested by humans, and hatch 
in the intestine, and pierce intestinal wall and migrate 
to various parts of the body through blood circulation 
(10). Since Toxocara sp. unable to mature under normal 
conditions in humans, the second-stage larvae create 
granulomatous inflammatory foci in these tissues after 
entering various body tissues and stimulation of the 
immune system (11).
Toxocara sp. may attack host’s brain and cause cerebral 
toxocariasis. Brain damage is caused by biological, 
physical, and chemical factors. It can lead to disability and 
even death. Since different brain damages have different 
results, identifying factors involved in brain damage 
helps determining pathophysiological mechanisms and 
predict neurological outcomes (12).
Toxocara can increase symptoms of seizure and epilepsy 
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using convenient sampling, and matched in terms of 
age, gender, and epidemiological data determining the 
socioepidemiological status, and living place (urban/
rural). 
After obtaining informed consents and completing 
demographic questionnaire, serum samples were taken 
from participants. The study was approved by the Ethical 
Committee of the university with code No. of Ajums.
REC.1392.116.
Five milliliters blood was taken from patients and 
control group under sterile condition, transferred to a 
qualified private laboratory in Ahvaz metropolitan city 
and centrifuged at 2000 rpm for 10 min; the separated 
serum was kept at -20 °C for doing the serologic tests. 
Due to potential error in test results, hemolyzed samples 
were not used.
Serology and Western blotting
The diagnostic test of Toxoplasma antibody was 
performed under the same conditions using ELISA 
method, and all samples were examined in terms of 
presence and level of anti-T. gondii IgG and IgM. 
The results were recorded by ELISA reader as optical 
absorbance. Quantitative examination of samples was 
performed by plotting standard absorbance curve with 
the help of optical absorbance of their positive and 
negative controls and their known concentrations.
In relation to Toxocara, the presence of IgG antibody 
was investigated in patients’ samples, and results were 
calculated according to optical absorbance and ELISA 
method against optical absorbance of control cases. 
Then, for confirmation, all positive results were also 
tested by Western blotting terms of Toxocara.
ELISA Toxocara sp. tests were performed with 
NOVATEC kit (GMBH, Germany) and Toxoplasma 
tests with EUROIMMUN kit (EUROIMMUN AG, 
Germany). According to the kit protocol, samples were 
first diluted at ratio of 1:101 using kit’s diluents solution, 
and amount of 100λ were poured into the wells. Positive 
and negative controls and calibration were also used.
Wells were incubated at room temperature for 30 min, 
and then rinsed three times. Next, 100 λ of conjugate 
was added and incubated again at room temperature. 
Following three times rinsing, 100λ of substrate was 
added and incubated. Finally, 100λ of stop solution was 
added and samples’ OD was read at wavelengths 450 
nm or 620 nm.
In Western blot method, LD BIO Diagnostic kit 
(France) was used. Briefly, strips were left adjacent to 
1/100 diluted serum samples at room temperature for 
90 min, and after minimum of three times rinsing with 
saline phosphate buffer containing 0.1% tween 20, strips 
were incubated at room temperature with anti-human 
immunoglobulin G antibody conjugate peroxidase, and 
following rinsing stages, diaminobenzidine substrate 
was added, and finally, reaction was stopped by several 
times rinsing with distilled water. Results containing 
bands with low molecular weight in 24-35 kDa range 
were considered positive (19).
Results
Study samples consisted of 141 patients with seizure 
disorder and 144 healthy people. In patients’ group, 84 
were male (59.57%) and 57 were female (40.43%), and 
the control group consisted of 68 males (47.22%) and 76 
females (52.78%). Mean age of participants was 2-39 yr. 
Epidemiologic and demographic characteristics of both 
groups are presented in Table 1.
Prevalence of Toxocara antibody in epileptic patients 
was significantly higher than that in the control group 
(P<0.002). According to ELISA results, 28 (19.85%) 
patients with seizure disorder had anti-Toxocara 
antibody (Table 2). Out of those with positive serums, 
18 (21.1%) were male, and 10 (17.5%) were female. Of 
the 144 healthy people, 2 (1.38%) had positive results.
Twenty patients with seizure disorder had anti-
Toxoplasma antibodies, while 39 out (30.46%) of the 
control group people also had this antibody (Table 2). 
Results are statistically significant (P=0.001). Of the 20 
serum positive patients, 12 (15%) were male.
The frequency of anti-Toxoplasma (IgG) and anti-
Toxocara antibodies measured between different 
types of seizures subtypes. As presented in Table 3 the 
frequency of Toxoplasma and Toxocara antibodies were 
higher in idiopathic and generalized epilepsy subtypes.
The prevalence of T. gondii and Toxocara was compared 
in various age subgroups in healthy and patient groups, 
and the difference was significant in Toxoplasma 
(P<0.001) and Toxocara (P<0.05) (Table 4, 5).
Samples from patients and control groups with positive 
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ELISA test in terms of anti-Toxocara antibody were 
also used for confirmatory Western blot test. Positive 
Western blot strips indicated the presence of anti-
Toxocara-specific antibody in samples with bands with 
low molecular weight in 24-35 kDa range.
Discussion
There is no report on anti-Toxoplasma or Toxocara 
antibodies between epileptic patients in Khuzestan 
Province. In the current investigation, measurement of 
such antibodies was performed considering the screening 
of epileptic patients and healthy persons. 
In the current investigation, frequency of anti-
Toxoplasma antibodies in case (14.18%) was lowers 
than control (30.46%) individuals. To survey anti-
Toxoplasma antibody in a serologic study conducted in 
Khoramabad, west of Iran, between 85 epileptic patients, 
and have reported 14.1% positive cases while only 4.7% 
of control individuals were positive. Considering case 
individuals, our result is in accordance with previous 
study conducted in west of Iran (7), while our control 
group had higher prevalence rate. The problem why anti-
Toxoplasma antibody frequency is lower in epileptic 
persons than control individuals needs more surveying. 
One cause maybe more supports and consequently higher 
care levels of epileptic patients, which are done by their 
parents. In the mentioned work, result for control group 
(4.7%) was lower than current investigation (30.46%) 
that regarding high prevalence rate of toxoplasmosis in 
normal population and declaration of investigator, needs 
cautious interpretation (7). Such difference in results 
could be due to differences in life style of both regions 
and self-health caring. 
In the current study, the frequency of anti-Toxocara 
antibody in epileptic and control groups was 19. 85% 
and 1.38%, respectively. In a different study, Zibaie, 
et al. investigated anti-Toxocara antibody’s frequency 
in 85 epileptic patients and 85 normal individuals 
that according to ELISA results the prevalence rate in 
cases was 11.8% and in controls was 3.5% (20) that 
the results of patients in our study (19.85%) are above 
than mentioned study. However, the results of control 
group of Zibaie et al. and our study (1.38%) are in 
accordance with together. In addition, they have tested 
anti-Toxocara positive samples with western-blotting 
method and confirmed the presence of low molecular 
weight bands in the zone of 24-35 kDa as positive test. 
In a study in Egypt, El-Tantawy and colleagues (21) have 
compared the prevalence of Toxoplasma and Toxocara 
in epileptic patients and control individuals. In that 
investigation, according to ELISA results, frequency of 
toxoplasmosis in patients and control groups was 60.6% 
and 43.3%, respectively and frequency of toxocariasis 
was 48.5% and 46.7% in patients and controls, 
respectively that such considerable difference between 
that study and current investigation could be due to 
cultural, health levels of both region and nutritional 
habits differences.
The hypothesis of protozoan and helminthes parasite 
relationships with neurological disturbances is evaluated 
in various studies. Khademvatan et al. investigated 
the frequency of anti-Toxoplasma and Toxocara IgG 
antibodies in schizophrenia patients in Khuzestan 
Province (22). Anti-Toxocara antibodies were 14% and 
4.3% respectively and anti-Toxoplasma antibodies were 
34% and 47.3% respectively (22). In another study, 
toxoplasmosis frequency was evaluated in schizophrenia 
patients and the frequency of anti-Toxoplasma antibodies 
was 67.7% in patients but 37.1% in control category 
(23). In another study, the frequency of anti-Toxoplasma 
antibody was evaluated in bipolar disorder patients, 
which was 31.6% in patients and 26.5% in control 
individuals (24). 
Soil contamination by parasite ova and oocyst is one of 
the probable ways that increases the risk of toxocariasis 
and toxoplasmosis, consequently the probability of 
neurologic damages. 
Previous study in Ahvaz showed high rates of soil 
infection in various parts of the city (46.5%) and this high 
rate of soil infection may accounts as a risk factor (25). 
Furthermore, the rate of infected cats with Toxocara is 
reported to be high in Ahvaz City. From 140 cat’s stools, 
45% were reported infected (26). Infection of public 
environments such as streets and valleys, parks and town 
cities and increased rates of infected cats with Toxocara, 
enhances the likelihood of children involvement with 
parasitic agents; then such factors account as a risk 
factor for epilepsy.
Current study showed that the frequency of anti-
Toxoplasma gondii IgM antibody in patients was 8.5% 
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and was meaningfully higher than control category 
(Table 2). One evidence, which confirms that contact 
with soil and cat may increase the chance of infection, is 
higher rate of IgM positive results in patients. However, 
interpretation of such finding needs more investigations. 
Furthermore, our study findings showed that 74.46% of 
patients had the history of soil contact; also, the history 
of cat contact observed in 29.07% of epileptic patients 
(Table 6). 
One of the problematic aspects in ELISA tests, which 
are based on excreted antigens of Toxocara, is cross-
reactivity with intestinal nematodes such as Ascaris that 
for prevention of this flaw the stool examination and/
or western blotting are performed on Toxocara positive 
samples, and because of higher specificity of western 
blotting method, we have used it in the present study. In 
the current investigation, 28 cases (19.85%) of epileptic 
serums were positive with ELISA method and all results 
were confirmed in western blotting method followed 
by rejection of probability of infection with intestinal 
nematodes. 
In the present study, the frequency of anti-Toxocara 
antibodies in epileptic patients was 19.85%. This 
result was confirmed by western blotting method and 
supported with previous studies (27-29). Kim et al. have 
investigated toxocariasis in hyper-eosinophilic patients, 
from their 97 serum samples, 63 cases were positive 
with ELISA method that after confirmative testing 
using western blotting 58 ELISA-positive were positive 
and other 5 ELISA-positive cases were negative with 
western blotting (30). Furthermore, 7 ELISA-negative 
cases were western blott-positive (30). In the current 
investigation, all tested samples with western blotting 
method showed the band with 24-35 kDa. Observed 
bands were mostly in the range of 24-35 kDa and a few 
numbers of samples had bands in the regions between 
75-100 kDa that this finding was supported earlier (28, 
29), although bands with high molecular weight has low 
sensitivity for detection of Toxocara.
In conclusion, the frequency of anti-Toxoplasma 
gondii is lower in epileptic than healthy individuals 
and this result is contrary to investigations that have 
reported higher levels of this antibody in such patient 
groups. ELISA results for Toxocara showed that the 
frequency of anti-Toxocara antibody in patients with 
seizure disorder might empower the probability that this 
parasite may cause central nervous system damage but 
such conclusion needs more surveys. Furthermore, our 
results showed that western blotting has high specificity 
and is a proper confirmative method for diagnosis of 
toxocariasis.
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Table 1. Demographic characteristics of the patient and control groups
Feature
Frequency



























































Table 2. Seropositivity of Toxoplasma gondii (IgG& IgM) and Toxocara IgG antibodies in epileptic patients and 
control group 
Patients’ group Healthy
n (%)  n (%) Sig OR CI95




12/141 (8.51%) 0/144 (0%) 0.005 0.9
0.87-0.96
Toxocara sp 28/141 (19.85%) 2/144 (1.38%) < 0.001 17.59 4.1 -75.42 
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Table 3:The distribution of Toxoplasma gondii (IgG)and Toxocara antibodies in 















Generalized 2/14 (14.28) 3/14 (21.42)
Table 4. The distribution of toxoplasmosis according to the age in epileptic patients and healthy control group
Patients group  Healthy













<0.001 0.4 0.005 -0.31
30-39 0/4 (0) 2/3(66.66% 0.1 3 0.6-14.86
Table 5. The distribution of toxocariasis according to the age in epileptic patients and healthy control group
Patients group  Healthy
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